The stock of Bristol-Myers Squibb Company (NYSE:BMY) decreased by -$0.44 on Monday to finish at $61.64, down -0.71 percent. The last five days have seen an average of 7,931,180 shares of common stock traded. 9 times new highs were reached in the current year, with a fall of -$10.31. The average number of shares traded over the last 20 days was 11,275,300, while the average volume over the last 50 days totaled 10,088,524.
BMY stock appreciated 0.37% since last month. On 08/08/23, the company’s shares reached a one-month low of $59.71. The stock touched a high of $81.43 on 02/06/23, after rallying from a low of $59.71 in 52 weeks. The price of BMY stock has declined by -14.33% or -$10.31 this year, reaching a new high 9 times. Still, the stock price is down -24.31% from the 52-week high.
Insider Transactions
BMY stock investors should be aware that Bristol-Myers Squibb Company (BMY) stock had its last reported insider trading activity 5 days ago on Aug 24. On Aug 24, EVP, Chief Human Resources Powell Ann sold 17,986 shares at $61.25 each. This transaction resulted in the insider making $1,101,642. On Aug 03, Plenge Robert M sold 732 shares at a price of US$61.14. After the transaction, the insider now owns 6,584 shares. EVP & President, Research VESSEY RUPERT had earlier sold 50,385 shares on May 03 for $67.06 a share. The transaction was completed for $3,378,818.
Valuation Metrics
Bristol-Myers Squibb Company (BMY) has a trailing price-to-earnings (P/E) ratio of 16.41. Beta for the stock is 0.40. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 2.81, the price-to-book (PB) ratio of 4.03, and the price-to-cash flow ratio of 11.86.
Company paid $0.57 per share in dividends, remained unchanged from $0.57 last year. A $0.03 dividend increase was reported on Thursday December 8 2022.
Financial Health
For the three months ended June 29, Bristol-Myers Squibb Company’s quick ratio was 1.30, while its current ratio was 1.40, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 1.08, and the total debt to equity ratio is 1.18. As far as profitability goes, gross margin for the trailing twelve months is 77.10% percent. Bristol-Myers Squibb Company’s EBITDA margin for the year ended June 29 was 42.37%, whereas its operating margin stood at 22.00% for the same period. Based on annual data, it had gross profit of $36.02 billion and revenue of $46.16 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. BMY’s return on assets (ROA) during the last 12 months has been 8.30%. There was a 11.80% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 25.00%.
Earnings Surprise
According to Bristol-Myers Squibb Company’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $11.23 billion, while revenues fell by -5.89% to $11.34 billion. It was predicted that Bristol-Myers Squibb Company’s quarterly earnings would be $1.75, but it ended up being $1.98, beating the consensus by -11.60%. EBITDA was $4.29 billion for the quarter. At the end of Bristol-Myers Squibb Company’s most recent quarter ended June 29, its liabilities totaled 61.46 billion, while its total debt was $39.21 billion. Equity owned by shareholders amounts to $2.09 billion.
Technical Picture
Here’s a quick look at Bristol-Myers Squibb Company’s (BMY) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 49.28%, suggesting the stock is Neutral, with a 15.36% historical volatility rate.
The stochastic %K and %D were 64.95% and 63.66% respectively, while the average true range (ATR) was 0.97. Based on the 14-day stochastic reading of 63.74%, the RSI (14) reading is 47.73%. On the 9-day MACD Oscillator, the stock is at -0.05, and the 14-day reading is at 0.10.
Analyst Ratings
In its analyst report released on July 14, 2023, HSBC Securities began covering Bristol-Myers Squibb Company (NYSE: BMY). The stock was rated as a Reduce by the brokerage firm. Analysts have assigned Bristol-Myers Squibb Company (BMY) an Overweight rating. BMY is a stock that is recommended for selling by 2 brokerage firms, while 11 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 12 others recommend it as a buy.
What is BMY’s price target for the next 12 months?
The current consensus forecast for the stock is between $56.00 and $90.00, with a median target price of $74.50. In analyzing these forecasts, the average price target given by analysts for Bristol-Myers Squibb Company (BMY) is $73.36.
